PT  - JOURNAL ARTICLE
AU  - Markowski, Mark C.
AU  - Velho, Pedro Isaacsson
AU  - Eisenberger, Mario A.
AU  - Pomper, Martin G.
AU  - Pienta, Kenneth J.
AU  - Gorin, Michael A.
AU  - Antonarakis, Emmanuel S.
AU  - Denmeade, Samuel R.
AU  - Rowe, Steven P.
TI  - Detection of Early Progression with <sup>18</sup>F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy
AID  - 10.2967/jnumed.120.259226
DP  - 2021 Sep 01
TA  - Journal of Nuclear Medicine
PG  - 1270--1273
VI  - 62
IP  - 9
4099  - http://jnm.snmjournals.org/content/62/9/1270.short
4100  - http://jnm.snmjournals.org/content/62/9/1270.full
SO  - J Nucl Med2021 Sep 01; 62
AB  - Bipolar androgen therapy (BAT) is an emerging treatment for metastatic castration-resistant prostate cancer (mCRPC). 18F-DCFPyL is a small-molecule PET radiotracer targeting prostate-specific membrane antigen (PSMA). We analyzed the utility of 18F-DCFPyL PET/CT in determining clinical response to BAT. Methods: Six men with mCRPC receiving BAT were imaged with 18F-DCFPyL PET/CT at baseline and after 3 mo of treatment. Progression by PSMA-targeted PET/CT was defined as the appearance of any new 18F-DCFPyL–avid lesion. Results: Three of 6 (50%) patients had progression on 18F-DCFPyL PET/CT. All 3 had stable disease or better on contemporaneous conventional imaging. Radiographic progression on CT or bone scanning was observed within 3 mo of progression on 18F-DCFPyL PET/CT. For the 3 patients who did not have progression on 18F-DCFPyL PET/CT, radiographic progression was not observed for at least 6 mo. Conclusion: New radiotracer-avid lesions on 18F-DCFPyL PET/CT in men with mCRPC undergoing BAT can indicate early progression.